Medical & Pediatric Oncology and Trials

(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS

(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)

(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS

(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS

(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS

(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1

(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)

(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA

(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP

(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B

(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER

(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER

(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS

(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE

(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART

(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY

(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE

(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES

(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS

(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS

(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE

(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA

(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA

(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES

(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D

(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST

(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.

(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA

(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY

(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES

(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE

(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA

(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.

(P 193) Recent Trends in Sarcoma Trials for Children in the United States

(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE

(P 195) MULTIPLE MYXOMA EFFECTIVELY TREATED WITH PAZOPANIB - A CASE REPORT

(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION

(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)

(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT

(P 200) EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES

(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY

(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS

(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM

(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE

(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES

(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902

(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE

(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY

(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY

(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS

(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES

(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND

(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION

(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY

(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER

(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND

(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS

(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE